SCHEMBL4032013

SCHEMBL4032013

Cc1nc(Cc2ccccc2)sc1C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.56
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 3/20 0.54
GAA P10253 2/20 0.54
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
HPGD P15428 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
NPC1 O15118 1/20 0.48
GPR52 Q9Y2T5 5/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
RAB9A P51151 2/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20894092 0.88 SMN1; SMN2 (0.69) KLKB1ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL27929449 0.85 SCD (0.53) KLKB1ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL27727783 0.83 CDC7 (0.47) KLKB1ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL4243016 0.83 SMN1; SMN2 (0.76) ALDH1A1SMN1; SMN2MAPTGAALMNA
SCHEMBL4030637 0.79 GPR52 (0.47) KLKB1LMNACYP1A2CYP3A4CYP2C19
SCHEMBL5034460 0.77 KDM4E (0.69) KLKB1ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL14108821 0.75 SMN1; SMN2 (0.56) KLKB1ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL6183830 0.75 SLC6A3 (0.50) KLKB1ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL26011296 0.75 LMNA (0.42) ALDH1A1SMN1; SMN2MAPTGAALMNA
SCHEMBL14109405 0.75 SMN1; SMN2 (0.55) KLKB1ALDH1A1SMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054408-A2 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL Novartis Ag (CH) 2009-05-06 EP claimed
WO-2008127349-A2 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL NOVARTIS AG (CH) 2008-10-23 WO claimed
EP-2121671-A1 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS Novartis AG (CH) 2009-11-25 EP disclosed
WO-2008074835-A1 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed